Zoetics v. Farmabase Saúde Animal: Tulathromycin Patent Appeal Dismissed
Zoetics brought a patent infringement action against Farmabase Saúde Animal over the veterinary antibacterial compound tulathromycin, covered by two Brazilian patents. The Court of Justice of São Paulo dismissed the appeal on 30 October 2024, increasing the winning party’s legal fee award to 15% of the case value.
Tulathromycin patent battle ends as São Paulo court dismisses appeal
Zoetics initiated an infringement action against Farmabase Saúde Animal Ltda in the São Paulo state court system, asserting two Brazilian patents — BRPI9810519B1 and BRPI9915480B1 — covering the veterinary antibacterial compound tulathromycin. The accused product is TREOXIN®, a tulathromycin-based drug marketed by Farmabase for animal health applications. The case was docketed under No. 1093529-81.2022.8.26.0100 and proceeded through the Court of Justice of São Paulo.
The appeal was dismissed on 30 October 2024. The court expressly dismissed the appeal without reaching a merits reversal of the lower decision, meaning the outcome of the first-instance proceedings was left intact. Additionally, the court exercised its authority under Article 85, §11 of the Brazilian Code of Civil Procedure to increase the attorney fee award owed to the prevailing party’s counsel to 15% of the case value — a standard appellate fee enhancement mechanism in Brazilian civil litigation.
The dismissal of the appeal without a substantive merits ruling suggests that the matter may have been resolved on procedural grounds, or that the lower court’s findings were sufficiently well-grounded to foreclose appellate review. The public record does not disclose the specific grounds for dismissal or the identity of the appellant, leaving the precise downstream implications for TREOXIN®’s market position and Farmabase’s freedom to operate somewhat uncertain pending further proceedings or enforcement action.
Filing to Appeal Dismissed in 0 days
Case closed 30 October 2024 by the Court of Justice of São Paulo
Appeal dismissed: what the ruling means for both parties
Appeal dismissed — no merits ruling issued
A dismissal of an appeal without a substantive merits determination means the appellate court declined to overturn or modify the lower court’s decision on the underlying infringement claims. The first-instance ruling is left intact. Under Brazilian civil procedure, appeal dismissal can be grounded in procedural deficiency, failure to meet admissibility requirements, or other non-merits grounds. The public record does not specify the precise basis here.
Procedural terminationFirst-instance victory preserved; fee award enhanced
The prevailing party at first instance retains that outcome, as the appeal was dismissed rather than granted. Importantly, the court invoked Article 85, §11 of the Brazilian Code of Civil Procedure to increase the winning counsel’s fee to 15% of the case value — a mechanism specifically designed to compensate attorneys for successful appellate defence. This enhancement signals judicial recognition of the merit of the first-instance result.
Lower ruling preservedAppeal fails; underlying infringement findings stand
The party that filed the appeal — identity not specified in the public record — did not obtain any reversal or modification of the lower decision. With the appeal dismissed, that party’s ability to re-litigate the same infringement question at this appellate level is exhausted. Any further challenge would require recourse to superior courts, subject to admissibility criteria under Brazilian law. The enhanced fee award also increases the financial cost of the failed appeal.
Appellate options exhausted at this levelTulathromycin IP enforcement position strengthened
With both BRPI9810519B1 and BRPI9915480B1 surviving appellate challenge, Zoetics’ enforcement position over tulathromycin compositions in Brazil is reinforced. Competitors and generic manufacturers in the Brazilian veterinary antibacterial market should treat these patents as active enforcement risks. The outcome may also influence parallel proceedings or licensing negotiations involving TREOXIN® or structurally similar formulations in the macrolide antibiotic space.
Veterinary pharma IP risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Zoetics | Individual | Veterinary pharmaceutical IP holder — patents BRPI9810519B1 and BRPI9915480B1 covering tulathromycinSearch in Eureka ↗ |
| Defendant | Farmabase Saúde Animal Ltda | Company | Farmabase Saúde Animal Ltda — Brazilian veterinary pharmaceutical company, maker of TREOXIN®Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The court’s language — ‘I DISMISS the appeal and I increase the fee due to the winning lawyer to 15% of the value of the case’ — is a standard appellate formula under Brazilian civil procedure. The dismissal is non-merits in form, leaving the first-instance decision undisturbed. The fee enhancement under CPC Art. 85, §11 is automatically triggered on appeal and signals the court’s view that the prevailing party’s appellate defence was substantively sound. No infringement finding is explicitly restated in this ruling, but neither is it displaced.
BRPI9810519B1 & BRPI9915480B1 — tulathromycin veterinary antibacterial patents
BRPI9810519B1 and BRPI9915480B1 are Brazilian patents covering tulathromycin, a semi-synthetic triamilide macrolide antibiotic developed specifically for veterinary use. Tulathromycin is characterised by its long tissue half-life and single-dose efficacy in treating bovine and porcine respiratory disease. The ‘B1’ designation under INPI’s numbering system indicates granted Brazilian patents, suggesting both have completed substantive examination and opposition phases. Their filing origins in the late 1990s are consistent with the compound’s original development timeline.
These patents are strategically significant because tulathromycin occupies a dominant position in the veterinary respiratory antibiotic market globally, marketed under brands including Draxxin® by Zoetis. In Brazil — a major livestock producer — controlling the IP around tulathromycin formulations has direct commercial value for both originator and generic manufacturers. The litigation against TREOXIN® indicates active enforcement intent, and the survival of both patents post-appeal means any Brazilian generic entrant in this space faces a credible infringement risk.
Should you run an FTO against BRPI9810519B1 and BRPI9915480B1?
Any company developing, manufacturing, or commercialising tulathromycin-based veterinary antibacterial products in Brazil should treat these patents as live enforcement risks. The São Paulo appellate dismissal confirms that Zoetics is actively defending this IP. R&D teams working on macrolide or triamilide antibiotic formulations for animal health applications — particularly for respiratory indications — should assess whether their compositions or methods fall within the claims of either patent before seeking Brazilian regulatory approval or commercial launch.
PatSnap Eureka’s FTO Search Agent can map your compound’s structural features and formulation parameters against the claim scope of BRPI9810519B1 and BRPI9915480B1, identify related Brazilian filings in the same priority family, and surface any published prior art that may support a validity challenge. For teams entering the Brazilian veterinary pharmaceutical market, an Eureka-powered FTO analysis provides a defensible clearance baseline and flags freedom-to-operate gaps before regulatory filing.
Run a freedom-to-operate analysis on BRPI9810519B1 to assess your product’s exposure
Run FTO in Eureka →Similar tulathromycin and veterinary antibiotic patent cases in Brazil
Explore related patent infringement actions involving macrolide and tulathromycin veterinary compounds heard before Brazilian state and federal courts.
What this case signals for the veterinary pharmaceutical IP landscape in Brazil
The dismissal reinforces tulathromycin patent enforceability in Brazil and raises the bar for generic challengers in the veterinary antibacterial market.
Brazilian courts will enhance fee awards when appellants fail on appeal
The court’s application of CPC Article 85, §11 to raise counsel fees to 15% of case value is a concrete deterrent to speculative appeals in patent infringement cases. Companies considering appeal of adverse first-instance patent rulings in Brazil should factor enhanced fee exposure into their litigation calculus.
Tulathromycin patent protection in Brazil appears durable post-appeal
With two tulathromycin patents surviving the appellate stage, Zoetics holds a reinforced IP position in the Brazilian veterinary market. Any company commercialising tulathromycin-based veterinary drugs in Brazil — including TREOXIN® competitors — should conduct a current FTO analysis against BRPI9810519B1 and BRPI9915480B1 before launch or continued commercialisation.
Zoetics v Farmabase — key questions answered
The Court of Justice of São Paulo dismissed the appeal on 30 October 2024, leaving the first-instance decision intact. The court also increased the winning party’s attorney fee award to 15% of the case value under Article 85, §11 of the Brazilian Code of Civil Procedure. No merits reversal was issued.
Zoetics asserted two Brazilian patents: BRPI9810519B1 and BRPI9915480B1. Both cover the veterinary antibacterial compound tulathromycin, a triamilide macrolide antibiotic. The accused product was TREOXIN®, a tulathromycin-based antibacterial drug marketed by Farmabase Saúde Animal.
Tulathromycin is a semi-synthetic triamilide macrolide antibiotic used primarily in veterinary medicine to treat respiratory diseases in cattle and pigs. It is valued for its long tissue half-life enabling single-dose treatment. Brazil’s large livestock industry makes tulathromycin a commercially significant compound, motivating originator companies to actively enforce formulation and compound patents against generic market entrants.
Under Brazilian civil procedure, dismissal of an appeal without a merits determination means the appellate court found the appeal inadmissible or procedurally deficient, without adjudicating the underlying infringement arguments. The first-instance ruling is preserved. Additionally, CPC Article 85, §11 permits the appellate court to increase the prevailing party’s attorney fee award, which occurred here.
The appeal dismissal does not constitute an express judicial validity ruling on either patent. However, the survival of both patents through appellate proceedings without reversal reinforces their de facto enforceability in Brazil. Competitors should treat both patents as active and conduct freedom-to-operate analysis before commercialising tulathromycin-based veterinary products in the Brazilian market.
PatSnap Eureka searches patents and litigation data to answer instantly.